Doxorubicinhydrochlorid Bendalis 2 mg/ml Ujerumani - Kijerumani - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

doxorubicinhydrochlorid bendalis 2 mg/ml

bendalis gmbh (8086604) - doxorubicinhydrochlorid - injektionslösung - teil 1 - injektionslösung; doxorubicinhydrochlorid (06460) 50 milligramm

Adriblastina 10 Ready To Use 10 mg Injektionslösung Ubelgiji - Kijerumani - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

adriblastina 10 ready to use 10 mg injektionslösung

pfizer - doxorubicin-hydrochlorid - injektionslösung - 10 mg - doxorubicin-hydrochlorid 10 mg - doxorubicin

Adriblastina 20 Ready To Use 20 mg Injektionslösung Ubelgiji - Kijerumani - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

adriblastina 20 ready to use 20 mg injektionslösung

pfizer - doxorubicin-hydrochlorid - injektionslösung - 20 mg - doxorubicin-hydrochlorid 20 mg - doxorubicin

Adriblastina 200 Ready To Use 200 mg Injektionslösung Ubelgiji - Kijerumani - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

adriblastina 200 ready to use 200 mg injektionslösung

pfizer - doxorubicin-hydrochlorid - injektionslösung - 200 mg - doxorubicin-hydrochlorid 200 mg - doxorubicin

Adriblastina 50 Ready To Use 50 mg Injektionslösung Ubelgiji - Kijerumani - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

adriblastina 50 ready to use 50 mg injektionslösung

pfizer - doxorubicin-hydrochlorid - injektionslösung - 50 mg - doxorubicin-hydrochlorid 50 mg - doxorubicin

Caelyx Konzentrat zur Herstellung einer Infusionslösung Uswisi - Kijerumani - Swissmedic (Swiss Agency for Therapeutic Products)

caelyx konzentrat zur herstellung einer infusionslösung

baxter ag - doxorubicini hydrochloridum - konzentrat zur herstellung einer infusionslösung - doxorubicini hydrochloridum 2 mg, n-(carbonyl-methoxypolyethylenglycoli 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolaminum natricum, phosphatidylcholinum ex soja hydrogenatum, cholesterolum, ammonii sulfas, saccharum, histidinum, acidum hydrochloridum aut natrii hydroxidum, aqua ad iniectabile q.s. ad suspensionem pro 1 ml corresp. natrium 0.054 mg. - zytostatikum - synthetika

Adriblastin Solution 10 mg/5 ml Injektionslösung Uswisi - Kijerumani - Swissmedic (Swiss Agency for Therapeutic Products)

adriblastin solution 10 mg/5 ml injektionslösung

pfizer ag - doxorubicini hydrochloridum - injektionslösung - doxorubicini hydrochloridum 10 mg, natrii chloridum corresp. natrium 17.7 mg, acidum hydrochloridum, aqua ad iniectabile q.s. ad solutionem pro 5 ml. - zytostatikum - synthetika

Adriblastin Solution 20 mg/10 ml Injektionslösung Uswisi - Kijerumani - Swissmedic (Swiss Agency for Therapeutic Products)

adriblastin solution 20 mg/10 ml injektionslösung

pfizer ag - doxorubicini hydrochloridum - injektionslösung - doxorubicini hydrochloridum 20 mg, natrii chloridum corresp. natrium 35.4 mg, acidum hydrochloridum, aqua ad iniectabile q.s. ad solutionem pro 10 ml. - zytostatikum - synthetika

Adriblastin Solution 50 mg/25 ml Injektionslösung Uswisi - Kijerumani - Swissmedic (Swiss Agency for Therapeutic Products)

adriblastin solution 50 mg/25 ml injektionslösung

pfizer ag - doxorubicini hydrochloridum - injektionslösung - doxorubicini hydrochloridum 50 mg, natrii chloridum corresp. natrium 88.5 mg, acidum hydrochloridum, aqua ad iniectabile q.s. ad solutionem pro 25 ml. - zytostatikum - synthetika

Zolsketil pegylated liposomal Umoja wa Ulaya - Kijerumani - EMA (European Medicines Agency)

zolsketil pegylated liposomal

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.